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Semi-parametric maximum likelihood estimates for ROC curves of
continuous-scale tests
Xiao-Hua Zhou † ∗ and Huazhen Lin ∗‡
Summary
In this paper, we propose a new semi-parametric maximum likelihood (ML) estimate of an ROC
curve that satisfies the property of invariance of the ROC curve and is easy to compute. We show
that our new estimator is
√
n-consistent and has an asymptotically normal distribution. Our extensive
simulation studies show the proposed method is efficient, robust, and simple to compute. Finally, we
illustrate the application of the proposed estimator in a real data set.
Key words: ROC curves; Sensitivity and specificity; Semi-parametric maximum likelihood esti-
mators.
1. Introduction
When the response of a diagnostic test is continuous, its diagnostic accuracy is best represented by
the receiver operating characteristic (ROC) curve [1]. Let F1 and F0 denote distribution functions of
the test result Y1 of a diseased subject and Y0 of a non-diseased subject, respectively. Then, the ROC
curve of the test can be written as
ROC(u) = 1− F1(F−10 (1− u)), (1)
where F−10 is the inverse function of F0, and u is the false positive rate (FPR) corresponding to a cut-off
point for positivity. It is well-known that the ROC curve of a test must be invariant to any monotone
increasing transformation of test results, a fundamental property of an ROC curve. Hence, any sensible
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estimation methods should have this property. In the statistical literature, many parametric, semi-
parametric, and non-parametric methods have been proposed for estimating an ROC curve. In general,
pure parametric methods do not possess the invariance property; the empirical non-parametric and
smoothing non-parametric methods have the property of invariance [2,3]. However, the jagged form of
the empirical ROC curve estimator can result in underestimating the true ROC curve as the true ROC
curve is a smooth function, and the intensive computation and challenging bandwidth selection of the
smoothing non-parametric estimators may affect their application in practice.
An intermediate strategy between pure parametric and non-parametric methods is a semi-parametric
approach. The most commonly used semi-parametric procedure to estimate the ROC curve is to assume
a parametric form for the ROC curve, but avoid making any additional parametric assumptions about
the distributions of test results. This type of semi-parametric method has the property of invariance.
In this paper, we focus on this type of semi-parametric method.
We assume that the ROC curve has the parametric form,
ROC(u) = G(α0 + α1H
−1(u)), (2)
where G and H are some known cumulative distribution functions. The most common choice for G and
H is the binormal form, G = H = Φ, where Φ is the cumulative distribution function of the standard
normal random variable.
Under the binormal model, several methods have been proposed by Metz et al. [4], Alonzo and Pepe
[5], Pepe and Cai [6], Zou and Hall [7], and Cai and Moskowitz [8]. The first approach, proposed by Metz
et al. [4] and denoted by MHS, is to first categorize continuous test data into ordinal-scale categorical
data and then to apply the maximum likelihood method to estimating the parameters in the binormal
model by assuming that the continuous variable can be approximated by a discrete variable with finite
support points; that is, the continuous distribution function can be specified by finite parameters,
which is difficult in practice. Furthermore, they use an ad hoc approach to reduce the number of the
parameters, hence, their resulting estimate is no longer a ML estimate even though their likelihood is
correct. The second approach, proposed by Alonzo and Pepe [5] and denoted by AP, is to estimate the
ROC curve by using procedures for fitting generalized linear models to binary data. The third approach,
proposed by Pepe and Cai [6] and denoted by PC, is to first write the ROC curve as the distribution
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of placement values and then to estimate the ROC curve by maximizing the pseudo likelihood function
of the estimated placement values. None of the above three methods is a truly maximum likelihood
(ML) estimator, and hence they do not possess the optimal property associated with ML estimators,
for example, fully efficient. The fourth method, proposed by Zou and Hall [7] and denoted by ZH, is to
use rank data to estimate the ROC curve by assuming semi-parametric distributions for test results of
diseased and non-diseased subjects and using maximum likelihood algorithms. However, the likelihood
function in the ZH method is a high-dimensional integral, and hence numerical methods include Monte
Carlo are required to evaluate the likelihood. Recently, Cai and Moskowitz [8] have proposed a profile
maximum likelihood approach from the raw data to estimate the ROC curve, denoted by CM; however,
their computation algorithm requires choosing reasonable initial values for a large number of nuisance
parameters, which may be difficult in practice when the sample size is large.
In this paper, we propose a new profile maximum likelihood approach to estimate the ROC curve.
Compared to the Cai and Moskowitz’ method, our method has a smaller number of nuisance parameters
to estimate. Furthermore, our estimator can be computed by using an algorithm that is based on
a recursive relationship among the nuisance parameters, without specifying initial values for a large
number of nuisance parameters. Our estimator is
√
n-consistent and has an asymptotically normal
distribution, and our extensive simulation studies show the proposed method is efficient, robust, and
simple to compute.
Since the binormal model is the most commonly used form for an ROC curve, from now on we
assume that the true ROC curve is defined by
ROC(u) = Φ(α0 + α1Φ
−1(u)), (3)
where Φ−1(·) is the inverse of the cumulative distribution of the standard normal distribution. Equiva-
lently, we can derive model (3) by assuming that there exists an unknown monotone increasing function
g(.) such that g(Y0) has the standard normal distribution and g(Y1) has a normal distribution with
mean µ and standard deviation σ. Then, the resulting ROC curve satisfies model (3) with α0 = µ/σ
and α1 = 1/σ.
The paper is organized as follows. In Section 2, we propose a semi-parametric maximum likelihood
estimator of an ROC curve and an algorithm for computing it, and develop asymptotic properties for
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the resulting estimator. In Section 3, we perform simulation studies to asses efficiency and robustness
of our estimator relative to the existing methods and to verify the validity of the asymptotic inferences
in finite samples. In Section 4, we illustrate the application of our method in an example.
2. Semi-parametric maximum likelihood estimate
Data available for making inferences consist of a random sample of size n1 from the diseased pop-
ulation with the unknown cumulative distribution function F1, {Y1j, j = 1, · · · , n1}, and a random
sample of size n0 from the non-diseased population, {Y0i, i = 1, · · · , n0}, with the unknown cumulative
distribution function F0. Denote n = n0 + n1.
Let f0 and f1 be the density functions of F0 and F1, respectively. Then, the likelihood function of
observations Y0i, i = 1, · · · , n0, and Y1j, j = 1, · · · , n1, is given by
L =
n0∏
i=1
f0(Y0i)
n1∏
j=1
f1(Y1j). (4)
Under model (3), we know that there exists a unknown increasing and differentiable function g(.) such
that g(Y0) has the standard normal distribution and g(Y1) has a normal distribution with mean µ and
standard deviation σ. Denote φ(x) to be the standard normal density function, therefore, we have that
f0(y) = φ(g(y))g
′(y) and f1(y) = φ(−α0 + α1g(y))α1g′(y). Hence we can write the likelihood function
(4) as
L =
n0∏
i=1
φ(g(Y0i))g
′(Y0i)
n1∏
j=1
φ(−α0 + α1g(Y1j))α1g′(Y1j). (5)
Consequently, the ML estimation of the ROC curve parameters α0 and α1 requires simultaneous esti-
mation of the unknown function g. Denote dF (x) = F (x)−F (x−), where ”−” represents the left limit.
Our approach to estimating α0, α1 and g is based on the nonparametric maximum likelihood approach
[9, 10, 11, 12], which seek to maximize the function L˜ given by
L˜ =
n0∏
i=1
φ(g(Y0i))dg(Y0i)
n1∏
j=1
φ(−α0 + α1g(Y1j))α1dg(Y1j);
that is,
L˜ =
n0∏
i=1
{Φ(g(Y0i))− Φ(g(Y0i−))}
n1∏
j=1
{Φ(−α0 + α1g(Y1j))− Φ(−α0 + α1g(Y1j−))} . (6)
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Denote the distinct ordered test results from the combined sample, Y0i’s and Y1j’s, by Y
∗
(1) < · · · <
Y ∗(I∗n−1), where I
∗
n− 1 is the number of distinct values among Y0i’s and Y1j’s. Therefore we can write the
likelihood function (6) as follows:
L˜ =
I∗n−1∏
r=1
(
Φ(g(Y ∗(r)))− Φ(g(Y ∗(r)−))
)k∗r (Φ(−α0 + α1g(Y ∗(r)))− Φ(−α0 + α1g(Y ∗(r)−)))`∗r , (7)
where frequency counts k∗r = #{Y0i = Y ∗(r), i = 1, · · · , n0} and `∗r = #{Y1j = Y ∗(r), j = 1, · · · , n1},
corresponding to non-diseased and diseased subjects at distinct ordered test results.
Let Ω = {all monotone increasing functions on(−∞,∞)}. Denote Y ∗(0) = −∞ and Y ∗(I∗n) = +∞.
Since Φ is monotonic and α1 > 0, to maximize L˜, we need to make the g(Y
∗
(r)) as large, and the g(Y
∗
(r)−)
as small. In addition, because g is monotonic and
∫ +∞
−∞ dΦ(g(y)) = 1, hence, any g ∈ Ω that maximizes
L˜ must satisfy
g(y) = g(Y ∗(r−1)), if Y
∗
(r−1) ≤ y < Y ∗(r)
for r = 1, · · · , I∗n. Hence the maximum likelihood estimate of g, denoted by ĝ, has to be a discrete
function that only jumps at observations Y ∗(1) < · · · < Y ∗(I∗n−1).
With C∗r = g(Y
∗
(r)), C
∗
0 = −∞, and C∗I∗n = +∞, we can write (7) as
Ln(θ, g) =
I∗n∏
r=1
(
Φ(C∗r )− Φ(C∗r−1)
)k∗r (Φ(−α0 + α1C∗r )− Φ(−α0 + α1C∗r−1))`∗r (8)
when g = ĝ. Therefore the estimation of ROC curve parameters α0 and α1, which are of primary
interest, requires simultaneous estimation of the I∗n − 1 number of nuisance parameters, C∗1 , · · · , C∗I∗n−1.
Using the same idea as in Metz et al. [4], we note that some of the jump points of ĝ, Y ∗(r)’s, can be
ignored for estimating α0 and α1, which means we can obtain the estimates of α0 and α1 with fewer
nuisance parameters. We state the results in Conclusion 1 below.
Denote
D(Y ∗(r)) =

2 if k∗r > 0 and `
∗
r > 0
1 if k∗r > 0 and `
∗
r = 0
0 if k∗r = 0 and `
∗
r > 0
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and
< = {Y ∗(r) : D(Y ∗(r)) = D(Y ∗(r+1)) ≤ 1, 1 ≤ r ≤ I∗n − 2} .
Each jump point in < has the same diseased status as its next contiguous jump point. Here, < includes
all jump points of a contiguous sequence with the same diseased status except the last point in the
sequence.
Conclusion 1 . The maximum likelihood estimates of α0 and α1 can be determined by some estimating
equations that don’t depend on those nuisance parameters C∗r = g(Y
∗
(r)) for which Y
∗
(r) belongs to <.
See Appendix A.1 for a proof of Conclusion 1. A practical consequence of the conclusion is that we
can ignore the jump points in < for estimating α0 and α1.
After deleting the points in <, we denote the remaining jump points of ĝ by Y(1) < · · · < Y(In−1)
and let Cr = g(Y(r)) for 1 ≤ r ≤ In − 1, C0 = −∞ and CIn = +∞. The MLE of θ = (α0, α1)T and
C = (C1, · · · , CIn−1)T can be obtained by maximizing
Ln(θ, g) =
In∏
r=1
(Φ(Cr)− Φ(Cr−1))kr (Φ(−α0 + α1Cr)− Φ(−α0 + α1Cr−1))`r , (9)
which is essentially (8) with I∗n replaced by In. Here, for 2 ≤ r ≤ In − 1, kr = #{Y(r−1) < Y0i ≤
Y(r), i = 1, · · · , n0} and `r = #{Y(r−1) < Y1j ≤ Y(r), j = 1, · · · , n1}; k1 = #{Y0i ≤ Y(1), i = 1, · · · , n0},
`1 = #{Y1j ≤ Y(1), j = 1, · · · , n1}, kIn = #{Y0i < Y(In−1), i = 1, · · · , n0}, and `In = #{Y1j < Y(In−1), j =
1, · · · , n1}.
To obtain the estimator of θ, in the paper, we propose a two-stage iterative procedure, alternating
the parametric and nonparametric estimation steps. Our idea for the nonparametric estimate is from
Kvam and Samaniego [11].
Given θ, we can find the estimator of C by maximizing the likelihood function (9) with respect to
6
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C. The estimator of C must satisfy the following (In − 1) score equations:
∂ log{Ln(θ, g)}
∂C1
= k1
φ(C1)
Φ(C1)
− k2 φ(C1)
Φ(C2)− Φ(C1)
+α1`1
φ(−α0 + α1C1)
Φ(−α0 + α1C1) − α1`2
φ(−α0 + α1C1)
Φ(−α0 + α1C2)− Φ(−α0 + α1C1) = 0,
∂ log{Ln(θ, g)}
∂Cr
= kr
φ(Cr)
Φ(Cr)− Φ(Cr−1) − kr+1
φ(Cr)
Φ(Cr+1)− Φ(Cr)
+α1`r
φ(−α0 + α1Cr)
Φ(−α0 + α1Cr)− Φ(−α0 + α1Cr−1)
−α1`r+1 φ(−α0 + α1Cr)
Φ(−α0 + α1Cr+1)− Φ(−α0 + α1Cr) = 0, 2 ≤ r ≤ In − 2,
∂ log{Ln(θ, g)}
∂CIn−1
= kIn−1
φ(CIn−1)
Φ(CIn−1)− Φ(CIn−2)
− kIn
φ(CIn−1)
1− Φ(CIn−1)
+α1`In−1
φ(−α0 + α1CIn−1)
Φ(−α0 + α1CIn−1)− Φ(−α0 + α1CIn−2)
−α1`In
φ(−α0 + α1CIn−1)
1− Φ(−α0 + α1CIn−1)
= 0. (10)
Inspection of (10) shows that finding the estimator of C in a closed form is a challenge. Hence, an
iterative algorithm is required. However, the standard Newton-Raphson iteration requires inversion of
an (In − 1) × (In − 1) matrix, and this computation can become a problem if In is large. But the
solution to the likelihood equations can be easily obtained if an initial estimate of C1 is given. Note
that `rkr = 0, for 1 ≤ r ≤ In; `r`r+1 = 0 and krkr+1 = 0 for 1 ≤ r ≤ In − 1. Suppose that we have
selected an initial value of C1, Cˇ1. Then from the first equation of (10), we obtain an estimate, Cˇ2, of
C2,
Cˇ2 =

α0
α1
+ 1
α1
Φ−1
(
Φ(−α0 + α1Cˇ1) + α1`2φ(−α0+α1Cˇ1)Φ(Cˇ1)k1φ(Cˇ1)
)
if k2 = 0
Φ−1
(
Φ(Cˇ1) +
k2Φ(−α0+α1Cˇ1)φ(Cˇ1)
α1`1φ(−α0+α1Cˇ1)
)
if `2 = 0
.
For r = 2, · · · , In−2, using the latest estimates, Cˇr−1 and Cˇr, of Cr−1 and Cr, we solve the rth equation
of (10) to obtain the following estimate of Cr+1:
Cˇr+1 =

α0
α1
+ 1
α1
Φ−1
(
Φ(−α0 + α1Cˇr) + α1`r+1φ(−α0+α1Cˇr)(Φ(Cˇr)−Φ(Cˇr−1))krφ(Cˇr)
)
if kr+1 = 0
Φ−1
(
Φ(Cˇr) +
kr+1φ(Cˇr)(Φ(−α0+α1Cˇr)−Φ(−α0+α1Cˇr−1))
α1`rφ(−α0+α1Cˇr)
)
if `r+1 = 0
.
Hence, given the initially chosen value of C1, Cˇ1, we can obtain the estimates, Cˇ2, . . . , CˇIn−1, of
C2, . . . , CIn−1 by solving the first In − 2 equations in (10). Now we are left to check whether those
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estimates also satisfy the last equation in (10),
Λ(CˇIn−2, CˇIn−1) = 0, (11)
where Λ(CIn−2, CIn−1) =
∂
∂CIn−1
log{Ln(θ, g)}. If Λ(CˇIn−2, CˇIn−1) = 0, the estimates, Cˇr, r = 1, . . . , In−
1, are the unique solution to Equation (10). If Λ(CˇIn−2, CˇIn−1) 6= 0, we need to update the initially
chosen value estimate, Cˇ1, and repeat the whole estimation process until the last equation in (10) is
satisfied.
Let θ0 be the true value of θ and g0 be the true function of g. Denote Cr0 = g0(Y(r)). In the following
Conclusion 2, we establish the relationship between C1 and Λ(CIn−2, CIn−1) to help in updating the
initially chosen value, Cˇ1. We provide a proof for Conclusion 2 in Appendix A.2.
Conclusion 2. Let θn = θ0 + op(1). For any initial chosen value Cˇ1 of C1, we let Cˇ2, . . . , CˇIn−1 be
the corresponding solution to the first (In − 2) equations in (10) and gˇ be the corresponding function
for g. Then, when n is large enough,
1. if Cˇ1 < C10, then Cˇr < Cr0 for r = 2, · · · , In − 1, and
Λ(CˇIn−2, CˇIn−1) =
∂
∂CIn−1
log{Ln(θ, g)}|g=gˇ,θ=θn < 0;
2. if Cˇ1 > C10, then Cˇr > Cr0 for r = 2, · · · , In − 1, and
Λ(CˇIn−2, CˇIn−1) =
∂
∂CIn−1
log{Ln(θ, g)}|g=gˇ,θ=θn > 0.
The results of Conclusion 2 provide a mechanism for updating the initially chosen value Cˇ1. If
Λ(CˇIn−2, CˇIn−1) < 0, we should increase our initially chosen value, Cˇ1. On the other hand, if Λ(CˇIn−2, CˇIn−1) >
0, we should decrease our initially chosen value, Cˇ1.
Given C, we can estimate θ by maximizing (9). We next outline the two-stage iterative procedure
for estimating θ and C.
• Step 1. We combine data from the diseased and non-diseased samples and order test results
in the combined sample, replace each test result by its true disease status. As a result, we
create a sequence of disease statuses for the combined sample. Denote the number of differ-
ent sequences with the same consecutive disease status by In. Then, count the number of el-
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ements in each sequence, denoted by k = {k1, · · · , kIn|
∑In
r=1 kr = n0} for non-diseased sub-
jects and ` = {`1, · · · , `In|
∑In
s=1 `s = n1} for diseased subjects. For example, if we have data
{5.38, 2.1, 4.5} for non-diseased subjects and {12.5, 10.4, 16.8, 5.1, 13.5} for diseased subjects, the
ordered test results in the combined sample are {2.1, 4.5, 5.1, 5.38, 10.4, 12.5, 13.5, 16.8}, and their
corresponding disease statuses are {no, no, di, no, di, di, di, di}, where no and di indicate a non-
diseased and diseased subject, respectively. Thus, in the above notation, we have In = 4 and
k1 = 2, k2 = 0, k3 = 1, k4 = 0 and `1 = 0, `2 = 1, `3 = 0, `4 = 4.
• Step 2. Given values of α0, α1, we estimate C1, · · · , CIn−1 by solving (10).
• Step 3. Given estimates of C1, · · · , CIn−1, we estimate α0 and α1 by maximizing (9) respect to α0
and α1.
• Step 4. Repeat Steps 2 and 3 until two successive values for (α0, α1, C1, · · · , CIn−1) converge.
Denote the convergent values of the iterate by α̂0, α̂1, Ĉ1, · · · , ĈIn−1.
• Step 5. The estimator ĝ, which is a discrete function that only jumps at observations Y ∗(1) < · · · <
Y ∗(I∗n−1), can be obtained by noting that for a sequence of M contiguous jump points which only
involve non-diseased subjects, we have
k∗r
Φ(C∗r )− Φ(C∗r−1)
= · · · = k
∗
r+M−1
Φ(C∗r+M−1)− Φ(C∗r+M−2)
=
∑r+M−1
j=r k
∗
j
Φ(C∗r+M−1)− Φ(C∗r−1)
. (12)
Since estimation of C∗r−1 and C
∗
r+M−1 has been obtained from Step 4, Ĉ
∗
r can be obtained by the
equality of the first and the last terms in the (12), and then, Ĉ∗r+1 can be obtained by the equality
of the second and the last terms in the (12) and so on. Similarly we can estimate values of g at
the jump points only involving diseased subjects by noting that for a sequence of M contiguous
jump points that only involves diseased subjects, we have
`∗r
Φ(θ′D∗r)− Φ(θ′D∗r−1)
= · · · = `
∗
r+M−1
Φ(θ′D∗r+M−1)− Φ(θ′D∗r+M−2)
=
∑r+M−1
j=r `
∗
j
Φ(θ′D∗r+M−1)− Φ(θ′D∗r−1)
,
where D∗r = (−1, C∗r )′.
Our final estimate of θ is actually a profile likelihood estimate, which maximizes the profile likelihood
for θ given by
PL(θ) = Ln(θ, ĝ(θ)),
9
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where ĝ(θ) maximizes the likelihood Ln(θ, g) for a fixed value of θ. This estimator is a function of the
test values only through their ranks. Using the results on the properties of maximum profile likelihood
estimates derived by Murphy and Van der Varrt[13], we can show that θ̂ is fully efficient and has the
following asymptotic distribution result:
n1/2(θ̂ − θ0)→ N(0,Σ0),
where
Σ0 = lim
n→∞
{
−∂
2 logLn(θ, g)
n∂θ∂θ′
+
(
∂2 logLn(θ, g)
n∂θ∂C′
)
×
(
∂2 logLn(θ, g)
n∂C∂C′
)−1(
∂2 logLn(θ, g)
n∂C∂θ′
)}−1
|θ=θ0,g=g0 .
Based on the estimates of α0 and α1, we can estimate the ROC curve by R̂OC(u) = Φ(α̂0+α̂1Φ
−1(u)).
Using the Taylor series expansion and the asymptotically normal result of θ̂, we have the following
asymptotic distribution result for the estimated ROC curve:
n1/2
(
R̂OC(u)−ROC(u)
)
→ N(0, σ2R),
where
σ2R = φ
2(α00 + α10Φ
−1(u))
 1
Φ−1(u)

′
Σ0
 1
Φ−1(u)
 ,
α00 and α10 are the true values of α0 and α1, respectively.
3. Simulation studies
In this section we conduct several simulation studies to (1) investigate the efficiency of the proposed
estimator by comparing with the existing estimators, (2) assess the robustness of the proposed estimator
against the departure from the binormal model, and (3) evaluate the accuracy of the asymptotic variance
estimator of the proposed estimator in finite sample sizes.
3.1 Efficiency
Since a valid program for the ZH method is no longer available and their Monte Carlo computation
is complicated, we will not include the ZH estimator in our simulation study but will investigate the
10
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performance of the ZH estimator by using the estimates from Zou and Hall [16] and from Zou’s disser-
tation in our examples. In this section we investigate the statistical efficiency of the five methods: the
proposed method, CM, MHS, AP and PC methods for estimating α0 and α1 in the binormal model and
for estimating the corresponding ROC curve by numerical studies. We use the root of mean squared
error (RMSE) to measure the performance of the various estimators for α0 and α1 and the sum of
RMSEs (SRMSE) for α0 and α1 as an overall performance measure. We evaluate the performance of
an estimator R̂OC(·) for the ROC curve using the average square errors (ASE), defined by
ASE =
1
ngrid
ngrid∑
k=1
{
R̂OC(uk)−ROC(uk)
}2
, (13)
where {uk, k = 1, · · · , ngrid} are the grid points at which the functions ROC(·) are estimated. In the
simulation studies, we choose ngrid = 100 and uk’s to be uniformly distributed over (0, 1). We choose 500
simulations for each scenario. Data for non-diseased subjects are generated from the standard normal
distribution, and data for diseased subjects are generated from N(2, 1.44); hence the area under the
ROC curve (AUC) is 0.9. We choose sizes of the diseased and non-diseased samples to be both equal and
unequal numbers, (n0, n1) = {(100, 100), (200, 100), (200, 200)}, to investigate the effect of the sample
sizes on the performance of the estimates. The results are displayed in Table 1 and Figure 1.
Table 1 gives bias, SD, RMSE and SRMSE of the resulting estimators for α0 and α1 by the five
methods. From Table 1 we see that in all cases, our estimator has the smallest SRMSE. Specifically,
our estimator consistently has smaller bias, standard error, and RMSE than the CM estimator due
to a smaller number of nuisance parameters to estimate: the number of the nuisance parameters are
50.82, 68.33 and 101.704 on average with SD = 7.17, 8.01 and 9.97, respectively in the proposed ap-
proach, and 200, 300 and 400 in the CM method for the case with (n0, n1) = (100, 100), (200, 100) and
(200, 200), respectively; Although the PC can have the smallest variance, its bias is also large and can
even be larger than its variance, which means that the bias is significant and could not be ignored; the
AP estimator is less biased than the PC estimator but has a larger variance than the PC estimator.
Table 1 also show that all the estimators are improved when n0 or n1 increases.
Table 1 goes here
Figure 1 depicts the distribution of the estimated ASEs for the ROC curve over the 500 replications
for each method. The proposed estimator and the CM estimator have comparable ASE, which is smaller
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than the other methods. The performance of the estimators MHS and AP is close to that of the proposed
one in this setting. The PC estimator has larger ASE than the other estimators. Further simulation
study (not reported here) shows that when the accuracy of a diagnostic test is not too high or the
sample size is large so that In can be large, the computation algorithm in the MHS method, which
collapses too many jump points, will lose some information.
Figure 1 goes here
Since the number of the nuisance parameters increase with the AUC decreasing for the proposed
method, the AUC can affect the comparison of the performance of the proposed approach and the CM
method. Therefore, we also conduct additional simulation studies with smaller AUCs. We generate data
for non-diseased subjects still from the standard nrmal distribution, but data for diseased subjects from
N(1,1) and N(0.5,1), resulting in the areas under the ROC curve (AUC) of 0.76 and 0.64, respectively.
Table 2 gives bias, SD, RMSE and SRMSE of the resulting estimators for α0 and α1 by the proposed
method and the CM method.
Table 2 goes here
From the result in Table 2, we see that SRMSEs of our method are less than or equal to those from
the CM; hence, our method may be a little bit better than the CM, or at a minimum, comparable to
the CM for the case with low AUC.
In summary, the CM, MHS, and AP estimators have similar efficiency as the proposed estimator
with the proposed estimator being slightly better in terms of SRMSEs in Tables 1 and 2. The AUC may
affect the performance of the proposed approach and the CM method, because the number of different
sequences with the same consecutive disease status, In, decreases with the AUC increasing, hence the
number of the parameters in our method decreases with the AUC increasing, while the number of the
parameters in the CM is still n+ 2 regardless the AUC increasing or decreasing.
3.2 Robustness
In the subsection, we compare robustness of the five methods to the departure from the binormal
assumption. It may be reasonable to expect a transformation to result in approximately normal data for
12
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non-diseased subjects, but since the population of diseased subjects is often a mixture of subpopulations
of subjects in different stages of the disease/infection, it seems much more reasonable to expect that
transformation would result in a mixture of normals rather than a single normal for diseased subjects. So,
to investigate the robustness of the binormal model, we simulate test responses of non-diseased subjects
from N(0, 1), but test responses of diseased subjects from the mixture of two normal distributions
N(1.2, 1.22), and N(2.2, 1.52), with the corresponding mixing proportions of 1/2 and 1/2. We set
(n0, n1) = {(100, 100), (200, 200)} to investigate the effect of the sample sizes on the performance of the
estimates.
Figures 2(A) and 3(A) plot the average of the estimated ROC curves over the 500 replications for
each method when the sample sizes are (100, 100) and (200, 200), respectively. The proposed estimator
has the smallest ASE and hence is the most robust estimate among the five ones considered here. The
CM, MHS and AP also have good robustness properties. The PC estimator has larger bias. Figures
2(B) and 3(B) depict the distribution of the ASE for the estimated ROC curves over the 500 replications
for each method when the sample sizes are (100, 100) and (200, 200), respectively. The AP estimator
has better ASE than the PC estimator, which means the AP estimator is more robust than the PC
estimator.
Figures 2 and 3 go here
We also conduct numerical studies with a larger number of the components in a normal mixture.
That is, we generate test results of non-diseased subjects from the standard normal distribution but test
results of diseased subjects from a mixture of three normal distributions N(1.2, 1.22), N(2.2, 1.52) and
N(2.2, 1) with the corresponding mixing proportions of 1/3, 1/3, and 1/3. The results (not reported
here) are similar to those in Figures 2 and 3 except that the PC estimator seems to have the largest bias
and ASE, suggesting that the robustness of the PC estimator may decrease as the number of components
in normal mixtures increases.
In summary, the CM, MHS, and AP estimators have similar robustness as the proposed estimators
with the proposed estimator to be slightly better.
3.3 Asymptotic inference in finite sample
Finally, we assess the accuracy of the variance estimate formula given in Section 2 in finite sample
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sizes. We investigate the performance of the variance estimate formula using the simulated data in
Sections 3.1 and 3.2. Based on 500 simulated data sets, we obtain 500 estimates of α̂0 and α̂1 and
their corresponding standard deviation estimates using the proposed method. From the estimates of
α0 and α1, we form the empirical standard deviations, denoted by SD, which can be regarded as an
approximation to the true standard deviations. We denote the average and the standard deviation of
500 estimated standard errors for the estimated α̂0 and α̂1 by SEave and SEstd, which summarize the
overall performance of the standard error formula. We report our results in Tables 3 and 4 for the
simulated binormal and mixture normal data in Sections 3.1 and 3.2, respectively. Our standard error
estimators are very close to the ”true” sample standard errors. The empirical CI coverage probabilities
are close to their nominal levels 0.95.
Tables 3 and 4 go here
4. An example
We illustrate the application of our newly proposed method in an example on the accuracy of
biomarkers for detecting pancreatic cancer [14]. This study examined two biomarkers, the antigenic
determinant, designated as CA125, and carbohydrate antigen designated as CA19-9. The data consist
of 51 measurements on subjects free of disease and 90 measurements on diseased subjects using the two
biomarkers. Here, we used the two biomarkers to illustrate the application of our methodology.
Although the binormal ROC model (3) may be robust, as shown in the simulation study, it is also
useful to assess whether model (3) is appropriate for the data before we make inferences on the ROC
curves of the CA125 and the CA19-9 using the binormal model. Here, we present a graphical method,
used by Cai and Moskowitz [8], to test model (3). Figure 4(a) and 5(a) plot the empirical ROC curve,
the maximum likelihood estimate of the ROC curve and its 95% pointwise confidence intervals (denoted
CI in Figure 4(a) and 5(a)) for CA19-9 and CA125, respectively, showing no obvious difference between
the empirical ROC curve and the estimated ROC curve based on the binormal model. So, the binormal
model is reasonable for the two biomarkers.
Figures 4 and 5 go here
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Table 5 lists the estimates for the coefficients α0 and α1, and Figure 4(b) and Figure 5(b) plot
the estimated ROC curves using the six methods for CA19-9 and CA125, respectively. Here, ZH’s
parameter estimates were taken from Zou and Hall [7] and Zou’s Ph.D dissertation. Note that the
parameters (α and β) in Zou and Hall [7] are related to our parameters, α0 and α1 in the following way:
α0 = α/β, α1 = 1/β.
Table 5 go here
From Table 5, we can see that the ZL, CM, AP, MHS and ZH estimates are quite similar. The PC
estimator is a little different from the others. The result is consistent with the simulation, which shows
that the PC estimator may be biased.
Discussion
In this paper we have proposed a semi-parametric MLE for the ROC curve under the bi-normal
ROC curve model (3). The estimator is asymptotically normal. The asymptotic results also hold for
the more general specification of parametric ROC curve model given by (2), for example, when G and
H are symmetric distributions and when H belongs to a location-scale family. Our simulation results
have indicated that the proposed estimators also have good finite-sample properties and have similar
efficiency and robustness as the CM, MHS, AP and ZH estimators with the proposed estimator is slightly
better than all the other estimators considered here in numerical implementation or efficiency. Same
with the CM and ZH estimators, our method is rank-based, the observations can be replaced by ranks.
Hanley15] has shown that the bi-normal ROC curve model for ordinal-scale tests enjoys a certain
degree of robustness against departure from the bi-normality assumption. Our own simulation studies
have also demonstrated this result. However, given limitations of any simulation study, we want to
emphasize that it is important to check the assumption of the bi-normality in any application; for
example one may use the graphical method suggested by Cai and Moskowitz[8] and illustrated in Section
4.
If the ROC curve of a diagnostic test depends on a subject’s covariates, we need to model covariate
effects on the ROC curves using a regression model. The most commonly used methods are direct
15
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regression models of covariates on ROC curves. For example, given the vector of covariates x, we can
model the effect of x on the ROC curves by the following model,
ROC(u, x) = G(α0 + α
′
1x+H(u)). (14)
For estimating such models, both the method of estimating equations and the quasi-likelihood method
have been proposed by Alonzo and Pepe [5] and Pepe and Cai [6], respectively. As shown in this
paper, without any covariates, our estimator slightly outperforms these two methods in the setting we
considered. Hence, it may be worthwhile to extend our methods to the setting where the ROC curve
depends on subject covariates.
In the paper, the two biomarkers CA19-9 and CA125 were analyzed ‘marginally’, without recognition
that each sample is really bivariate (two diagnostic tests on the same patients). Zou and Hall [16] and
Metz, Herman and Roe [17] proposed methods to estimate ROC curve from paired samples. We will
extend our method to the data with potential dependence in another paper.
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Appendix
We first define some additional notation that is needed to prove Conclusions 1, 2 and Theorem 1. Define
Dr = (−1, Cr)′, D∗r = (−1, C∗r )′, Dr0 = (−1, Cr0)′, Dˇr = (−1, Cˇr)′ and b0 = limn1/(n0 + n1).
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A.1 Proof of Conclusion 1
Let λn(θ, g) =
1
n
logLn(θ, g), where Ln(θ, g) is defined by (8). Denote C
∗ = (C∗1 , · · · , C∗I∗n−1)′, C∗r =
g(Y ∗(r)), and Y
∗
(1) < · · · < Y ∗(I∗n−1) to be distinct ordered test results of Y0i, i = 1, · · · , n0 and Y1j, j =
1, · · · , n1. It can be shown that the MLE of θ and C∗ must satisfy the following equations:
∂λn(θ, g)
∂C∗r
=
1
n
(
k∗r
Φ(C∗r )− Φ(C∗r−1)
− k
∗
r+1
Φ(C∗r+1)− Φ(C∗r )
)
φ(C∗r )
+
1
n
(
`∗r
Φ(θ′D∗r)− Φ(θ′D∗r−1)
− `
∗
r+1
Φ(θ′D∗r+1)− Φ(θ′D∗r)
)
α1φ(θ
′D∗r) = 0, (15)
for 1 ≤ r ≤ I∗n − 1, and
∂λn(θ, g)
∂θ
=
1
n
I∗n−1∑
r=2
`∗r
φ(θ′D∗r)D
∗
r − φ(θ′D∗r−1)D∗r−1
Φ(θ′D∗r)− Φ(θ′D∗r−1)
+
1
n
`∗1
φ(θ′D∗1)D
∗
1
Φ(θ′D∗1)
− 1
n
`∗I∗n
φ(θ′D∗I∗n−1)D
∗
I∗n−1
1− Φ(θ′D∗I∗n−1)
= 0, (16)
where k∗r = #{Y0i = Y ∗(r), i = 1, · · · , n0} and `∗r = #{Y1j = Y ∗(r), j = 1, · · · , n1}. If both Y ∗(r) and Y ∗(r+1)
correspond to non-diseased subjects, then `∗r = `
∗
r+1 = 0 , k
∗
r < 0 and k
∗
r+1 < 0. Hence, rom (15),
we have k
∗
r
Φ(C∗r )−Φ(C∗r−1) =
k∗r+1
Φ(C∗r+1)−Φ(C∗r ) . Extending this argument to a sequence of M contiguous jump
points which only involve non-diseased subjects, we have
k∗r
Φ(C∗r )− Φ(C∗r−1)
= · · · = k
∗
r+M−1
Φ(C∗r+M−1)− Φ(C∗r+M−2)
,
which is equal to ∑r+M−1
j=r k
∗
j
Φ(C∗r+M−1)− Φ(C∗r−1)
.
Similar arguments indicate that for a sequence ofM contiguous jump points which only involves diseased
subjects, we have
`∗r
Φ(θ′D∗r)− Φ(θ′D∗r−1)
= · · · = `
∗
r+M−1
Φ(θ′D∗r+M−1)− Φ(θ′D∗r+M−2)
,
which is equal to ∑r+M−1
j=r `
∗
j
Φ(θ′D∗r+M−1)− Φ(θ′D∗r−1)
.
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Therefore, if we denote Y(1) < · · · < Y(In−1) to be the last point of contiguous jump points with same
disease status, and Cr = g(Y(r)), r = 1, · · · , In − 1, for 1 ≤ r ≤ In − 1, we can write (15) and (16) as
∂λn(θ, g)
∂Cr
=
1
n
(
kr
Φ(Cr)− Φ(Cr−1) −
kr+1
Φ(Cr+1)− Φ(Cr)
)
φ(Cr)
+
1
n
(
`r
Φ(θ′Dr)− Φ(θ′Dr−1) −
`r+1
Φ(θ′Dr+1)− Φ(θ′Dr)
)
α1φ(θ
′Dr) = 0 (17)
and
∂λn(θ, g)
∂θ
=
1
n
In−1∑
r=2
`r
φ(θ′Dr)Dr − φ(θ′Dr−1)Dr−1
Φ(θ′Dr)− Φ(θ′Dr−1)
+
1
n
`1
φ(θ′D1)D1
Φ(θ′D1)
− 1
n
`In
φ(θ′DIn−1)DIn−1
1− Φ(θ′DIn−1)
= 0, (18)
respectively, where kr and `r are defined in Section 2. Note that (17) and (18) do not depend on the
nuisance parameters C∗r = g(Y
∗
(r))’s with Y
∗
(r) ∈ <. Hence Conclusion 1 follows.
A.2 Proof of Conclusion 2
Let Cˇ1 = C10 + ε for any ε < 0 and Cˇ2, · · · , CˇIn−1 be the solution to the first In − 2 score equations in
(10) given C1 = Cˇ1 and gˇ is the corresponding function for g. Define Φˇr = Φ(Cˇr) for r = 1, · · · , In − 1.
Let ΦˇIn be the solution to the following equation:
Gn(x) ≡ kIn−1
φ(CˇIn−1)
Φ(CˇIn−1)− Φ(CˇIn−2)
− kIn
φ(CˇIn−1)
x− Φ(CˇIn−1)
+α1`In−1
φ(θ′DˇIn−1)
Φ(θ′DˇIn−1)− Φ(θ′DˇIn−2)
− α1`In
φ(θ′DˇIn−1)
x− Φ(θ′DˇIn−1)
= 0.
Since
kr
n
− (1− b0) [Φ(Cr0)− Φ(Cr−1,0)] = op(1) (19)
and
`r
n
− b0 [Φ(θ′0Dr0)− Φ(θ′0Dr−1,0)] = op(1), (20)
for 1 ≤ r ≤ In, we have
Gn(x)− gn(x) = op(1), (21)
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where
gn(x) = (1− b0)φ(CˇIn−1)
[
Φ(CIn−1,0)− Φ(CIn−2,0)
Φ(CˇIn−1)− Φ(CˇIn−2)
− 1− Φ(CIn−1,0)
x− Φ(CˇIn−1)
]
+b0α1φ(θ
′DˇIn−1)
[
Φ(θ′DIn−1,0)− Φ(θ′DIn−2,0)
Φ(θ′DˇIn−1)− Φ(θ′DˇIn−2)
− 1− Φ(θ
′DIn−1,0)
x− Φ(θ′DˇIn−1)
]
. (22)
Since Gn(ΦˇIn) = 0, we have
gn(ΦˇIn) = op(1). (23)
Furthermore, we have,
1
n
∂
∂CIn−1
log{Ln(θ, g)}|g=gˇ
= (1− b0)φ(CˇIn−1)
[
Φ(CIn−1,0)− Φ(CIn−2,0)
Φ(CˇIn−1)− Φ(CˇIn−2)
− 1− Φ(CIn−1,0)
1− Φ(CˇIn−1)
]
+b0α1φ(θ
′DˇIn−1)
[
Φ(θ′DIn−1,0)− Φ(θ′DIn−2,0)
Φ(θ′DˇIn−1)− Φ(θ′DˇIn−2)
− 1− Φ(θ
′DIn−1,0)
1− Φ(θ′DˇIn−1)
]
+ op(1)
= gn(1) + op(1) = gn(Φ(CIn,0)) + op(1),
Hence, if the assumption that
Φˇr > Φ(Cr0) (24)
holds for r = In, by (23) and the fact that gn(x) is a strict increasing function of x, we obtain
1
n
∂
∂CIn−1
log{Ln(θ, g)}|g=gˇ < 0
for sufficient large ε, and hence the second part of Conclusion 2 follows.
Now we prove the assumption (24) holds for r = 2, · · · , In. We use the inductive method to prove
(24). The inductive method relies on In − 1 steps. The first step consists of an conclusion for r = 2.
From (10), we see that Cˇ2 satisfies
G1(x) =
1
n
∂
∂C1
log{Ln(θ, g)}|C1=Cˇ1,C2=x
=
k1
n
φ(Cˇ1)
Φ(Cˇ1)
− k2
n
φ(Cˇ1)
Φ(x)− Φ(Cˇ1)
+α1
`1
n
φ(θ′Dˇ1)
Φ(θ′Dˇ1)
− α1 `2
n
φ(θ′Dˇ1)
Φ(θ′x˜)− Φ(θ′Dˇ1)
= 0. (25)
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By (19) and (20), we have
G1(x)− g1(x) = op(1), (26)
where
g1(x) = (1− b0)φ(Cˇ1)
{
Φ(C10)
Φ(Cˇ1)
− Φ(C20)− Φ(C10)
Φ(x)− Φ(Cˇ1)
}
+b0α1φ(θ
′Dˇ1)
{
Φ(θ′D10)
Φ(θ′Dˇ1)
− Φ(θ
′D20)− Φ(θ′D10)
Φ(θ′x˜)− Φ(θ′Dˇ1)
}
,
Thus by (25) and (26), we have g1(Cˇ2) = op(1). Since Cˇ1 < C10, g1(C20) < 0. Note that g1(C2) is an
increasing function of C2. Hence
Cˇ2 < C20,
and (24) holds for r = 2.
The step j consists of showing that the inequality (24) is true for r = j + 1 if the inequality (24)
holds when r = 1, . . . , j. Using the same argument as before with r = 2, we can prove that (24) holds
for r = j + 1 given Φˇr < Φ(Cr0), r = 2, · · · , j. Hence the inequality (24) holds for r ≤ In.
Using the same argument as before with Cˇ1 = C10 + ε, we can obtain the first part of Conclusion 2.
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Figure 1: The distribution of ASE for the estimated ROC curve from the binormal simulated model in
Section 3.1 over the 500 replications.
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Table 1: Estimates of (α0, α1) compared with their actual values over the 500 replications for the
binormal simulated data with high AUC in section 3.1.
α0 = 2/1.2 α1 = 1/1.2
n0 n1 Method Bias SD RMSE Bias SD RMSE SRMSE
100 100 ZL 0.038 0.209 0.212 0.012 0.137 0.137 0.349
CM 0.074 0.213 0.226 0.043 0.141 0.148 0.373
MHS 0.002 0.212 0.212 -0.033 0.142 0.146 0.358
AP 0.025 0.225 0.226 0.041 0.164 0.169 0.395
PC -0.105 0.169 0.199 -0.163 0.088 0.185 0.384
200 100 ZL 0.028 0.180 0.182 0.009 0.113 0.113 0.295
CM 0.039 0.184 0.188 0.022 0.115 0.117 0.305
MHS 0.022 0.208 0.209 -0.014 0.142 0.143 0.352
AP 0.027 0.191 0.193 0.034 0.131 0.136 0.328
PC -0.105 0.142 0.177 -0.129 0.092 0.158 0.335
200 200 ZL 0.016 0.140 0.141 0.002 0.093 0.093 0.234
CM 0.024 0.142 0.144 0.012 0.094 0.095 0.239
MHS -0.009 0.137 0.137 -0.014 0.102 0.103 0.240
AP 0.009 0.144 0.145 0.017 0.103 0.104 0.249
PC -0.108 0.123 0.164 -0.132 0.087 0.158 0.322
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Table 2: Estimates of (α0, α1) compared with their actual values over the 500 replications for the
binormal simulated data with low AUC in section 3.1.
α0 = 1/1 α1 = 1/1
n0 n1 Method Bias SD RMSE Bias SD RMSE SRMSE
100 100 ZL 0.025 0.166 0.168 0.003 0.124 0.124 0.292
CM 0.031 0.168 0.171 0.021 0.125 0.126 0.298
200 100 ZL 0.009 0.134 0.134 0.006 0.102 0.102 0.236
CM 0.017 0.137 0.138 0.017 0.103 0.105 0.243
200 200 ZL 0.008 0.111 0.111 -0.001 0.082 0.082 0.193
CM 0.015 0.112 0.113 0.011 0.083 0.084 0.197
α0 = 0.5/1 α1 = 1/1
n0 n1 Method Bias SD RMSE Bias SD RMSE SRMSE
100 100 ZL 0.025 0.151 0.153 0.012 0.115 0.116 0.269
CM 0.023 0.152 0.153 0.024 0.111 0.114 0.267
200 100 ZL 0.005 0.122 0.122 0.021 0.095 0.097 0.219
CM 0.010 0.121 0.121 0.020 0.096 0.098 0.219
200 200 ZL 0.004 0.100 0.100 0.004 0.075 0.075 0.175
CM 0.010 0.099 0.100 0.013 0.075 0.076 0.176
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Table 3: Average(SEave) and standard deviation (SEstd) of the standard error estimator over the 500
replications for the binormal simulated data with high AUC in Section 3.1
α0 = 2/1.2 α1 = 1/1.2
n0 n1 SD SEave(SEstd) Coverage SD SEave(SEstd) Coverage
50 100 0.230 0.226(0.049) 0.939 0.160 0.161(0.043) 0.917
100 100 0.209 0.202(0.040) 0.920 0.137 0.133(0.031) 0.922
200 100 0.180 0.186(0.035) 0.931 0.113 0.113(0.024) 0.933
200 200 0.140 0.140(0.020) 0.947 0.093 0.091(0.015) 0.929
Table 4: Average(SEave) and standard deviation (SEstd) of the standard error estimator over the 500
replications for the mixture normal data in Section 3.2
α0 α1
n0 n1 k* SD SEave(SEstd) SD SEave(SEstd)
50 50 3 0.239 0.244(0.034) 0.159 0.167(0.036)
100 100 3 0.164 0.168(0.016) 0.111 0.113(0.018)
100 100 2 0.155 0.161(0.014) 0.097 0.105(0.015)
200 200 2 0.106 0.112(0.006) 0.068 0.071(0.007)
*where k is the number of terms in the mixture of normals for the diseased data.
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Table 5: Estimates of (α0, α1) for CA19-9 and CA125 as diagnostic markers of pancreatic cancer
CA19-9 CA125
method α̂0(SD) α̂1(SD) α̂0(SD) α̂1(SD)
ZL 1.192(0.158) 0.431(0.081) 0.7277(0.1858) 1.005(0.1309)
MHS 1.177(0.160) 0.399(0.082) 0.7240(0.185) 1.001(0.137)
CM 1.235(0.129) 0.480(0.074) 0.7605(0.234 ) 1.0648(0.154)
AP 1.142(0.153) 0.468(0.110) 0.7594(0.251 ) 1.1295(0.255)
PC 1.343(0.192) 0.490(0.040) 0.6180(0.202) 0.8421( 0.139)
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Figure 2: The diseased data are from a mixture of two normal distributions, but modeled with the
binormal model when n0 = n1 = 100. (A) The average of the estimated ROC curves; (B) the distribution
of ASE for the estimated ROC curves over the 500 replications.
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Figure 3: The diseased data are from a mixture of two normal distributions, but modeled with the
binormal model when n0 = n1 = 200. (A) The average of the estimated ROC curves; (B) the distribution
of ASE for the estimated ROC curves over the 500 replications.
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Figure 4: Estimated ROC curves of CA19-9 in the pancreatic cancer data set.
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Figure 5: Estimated ROC curves of CA125 in the pancreatic cancer data set.
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